Categories: BuildingBusinessChemicalLearnMaterialsMedtechPlatformServiceTechnology
ViaNautis is exploiting its proprietary technology, polyNaut®, a nanovesicle platform using advanced polymer materials and machine learning, to direct nucleic a
Investors 3
Funding Rounds 1
| Date | Series | Amount | Investors |
| 18.11.2023 | Series A | $25M | - |
Mentions in press and media 3
| Date | Title | Description |
| 18.11.2023 | ViaNautis raises £20 million Series A financing to drive the next generation of genetic nanomedicines | ViaNautis Bio, a ground-breaking nanomedicine company at the forefront of genetic therapies, has completed its Series A funding round, raising £20 million.
Formerly known as SomaServe, ViaNautis has secured support from a consortium of pro... |
| 13.11.2023 | 4BIO Capital jointly leads $25 million Series A financing of ViaNautis Bio | - ViaNautis’s proprietary drug delivery platform polyNaut® is designed to deliver genetic therapeutic payloads across difficult-to-penetrate biological barriers, developing new medicines for diseases with unmet clinical need |
| 13.11.2023 | ViaNautis Bio Raises $25M in Series A Financing | ViaNautis (formerly known as SomaServe), a Cambridge, UK-based nanomedicine company, raised $25M in Series A funding.
The round was led by 4BIO Capital, BGF, and UCB Ventures with participation from the Cystic Fibrosis Foundation, Eli Lilly... |
Reviews 0
